SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-007373
Filing Date
2023-03-10
Accepted
2023-03-10 17:31:36
Documents
12
Period of Report
2023-03-10
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K eypt-20230310.htm   iXBRL 8-K 51340
  Complete submission text file 0000950170-23-007373.txt   165283

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT eypt-20230310_pre.xml EX-101.PRE 9457
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT eypt-20230310.xsd EX-101.SCH 2475
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT eypt-20230310_lab.xml EX-101.LAB 12806
6 EXTRACTED XBRL INSTANCE DOCUMENT eypt-20230310_htm.xml XML 4523
Mailing Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472
Business Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472 617-926-5000
EyePoint Pharmaceuticals, Inc. (Filer) CIK: 0001314102 (see all company filings)

IRS No.: 262774444 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-51122 | Film No.: 23725006
SIC: 3826 Laboratory Analytical Instruments